title: Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
abstract: Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl(17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.
authors.affiliation: Universitätsklinikum Carl Gustav Carus der Technische Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany;
authors.forename: Jan M
authors.initials: JM
authors.lastname: Middeke
authors.forename: Min
authors.initials: M
authors.lastname: Fang
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Cornelissen
authors.forename: Brigitte
authors.initials: B
authors.lastname: Mohr
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: Michael
authors.initials: M
authors.lastname: Stadler
authors.forename: Jaime
authors.initials: J
authors.lastname: Sanz
authors.forename: Herrad
authors.initials: H
authors.lastname: Baurmann
authors.forename: Gesine
authors.initials: G
authors.lastname: Bug
authors.forename: Kerstin
authors.initials: K
authors.lastname: Schäfer-Eckart
authors.forename: Ute
authors.initials: U
authors.lastname: Hegenbart
authors.forename: Tilmann
authors.initials: T
authors.lastname: Bochtler
authors.forename: Christoph
authors.initials: C
authors.lastname: Röllig
authors.forename: Friedrich
authors.initials: F
authors.lastname: Stölzel
authors.forename: Roland B
authors.initials: RB
authors.lastname: Walter
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ehninger
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: Bob
authors.initials: B
authors.lastname: Löwenberg
authors.forename: Johannes
authors.initials: J
authors.lastname: Schetelig
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D063868:Patient Outcome Assessment; D012074:Remission Induction; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous; D055815:Young Adult